Ionis cuts TRYNGOLZA outlook after slower launch despite Q3 revenue growth
+5 new sources since this summary was written
Ionis Pharmaceuticals reported third-quarter 2026 revenue of $243M, up from $157M a year earlier, and a GAAP net loss of $110M. The company reduced 2026 TRYNGOLZA sales guidance to approximately $50M from $100M-$110M, citing a slower launch ramp. It reaffirmed total 2026 revenue guidance of $875M-$900M and highlighted continued growth from DAWNZERA and progress across its pipeline.
Why it matters
The lower TRYNGOLZA outlook reduces near-term expectations for Ionis's newest commercial product, while the unchanged total revenue forecast limits the immediate effect on company-wide guidance. Ionis said the slower launch reflects the time needed to establish a new treatment approach and that it remains confident in the drug's long-term potential.
Key facts
- 1Ionis reported third-quarter GAAP EPS of -$0.66. seekingalpha.com
- 2TRYNGOLZA generated $9 million in U.S. net product sales during the third quarter of 2026. rttnews.com
- 3The revised TRYNGOLZA outlook of approximately $50 million compares with the previous range of $100 million to $110 million. rttnews.com
- 4Ionis ended the quarter with $1.9 billion in cash, cash equivalents and short-term investments. rttnews.com
- 5DAWNZERA produced $37 million in U.S. net product sales in the third quarter of 2026. rttnews.com
Summary written by AlphAI AI Desk from 19 of 19 sources. Not investment advice. Figures are as stated by the linked sources.